Related content

Erlotinib

By Robinson Dean M.   Keating Gillian M.   Perry Caroline M.  

American Journal of Cancer, Vol. 4, Iss. 4, 2005-01 ,pp. : 247-252

Adis International

Access to resources Recommend Favorite

Erlotinib in the first-line treatment of non-small-cell lung cancer

By D'Arcangelo Manolo   Cappuzzo Federico  

Expert Review of Anticancer Therapy, Vol. 13, Iss. 5, 2013-05 ,pp. : 523-533

Informa Healthcare

Access to resources Recommend Favorite

Toxicity manifesting as cosmetic hair alterations during erlotinib treatment

By Kudo Kenichiro   Fujiwara Keiichi   Tsushima Mizuho   Mizuta Makoto   Matsuo Kiyoshi   Yonei Toshiro   Sato Toshio  

Acta Oncologica, Vol. 50, Iss. 1, 2011-01 ,pp. : 146-148

Informa Healthcare

Access to resources Recommend Favorite

Erlotinib: success of a molecularly targeted agent for the treatment of advanced pancreatic cancer

By Welch Stephen A   Moore Malcolm J  

Future Oncology, Vol. 3, Iss. 3, 2007-06 ,pp. : 247-254

Future Medicine

Access to resources Recommend Favorite

Keratoacanthomas associated with imatinib mesylate

By Balagula Yevgeniy   Busam Klaus J.   Carvajal Richard D.   Wolchok Jedd D.   Myskowski Patricia L.  

Acta Oncologica, Vol. 50, Iss. 4, 2011-05 ,pp. : 593-595

Informa Healthcare

Access to resources Recommend Favorite